Literature DB >> 11528618

High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.

S Van Biervliet1, M Van Winckel, E Robberecht, I Kerremans.   

Abstract

The authors describe 4 children with recurrent stenosis and persistent esophagitis after secondary repair of a long gap esophageal atresia. They underwent an esophageal reconstruction by elongation of the lesser gastric curvature according to Schärli at the age of 11 to 14 months. All had esophagitis grade III to IV (Savary-Miller classification), esophageal stenosis, and failure to thrive. Effective treatment of the esophagitis and prevention of stenosis consisted in high doses of omeprazole (1.9 to 2.5 mg/kg/d). After this treatment, the need for esophageal dilatation disappeared, and nutritional status normalized. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528618     DOI: 10.1053/jpsu.2001.26388

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Managing gastroesophageal reflux disease in children: The role of endoscopy.

Authors:  Helena As Goldani; Daltro La Nunes; Cristina T Ferreira
Journal:  World J Gastrointest Endosc       Date:  2012-08-16

Review 2.  Current knowledge on esophageal atresia.

Authors:  Paulo Fernando Martins Pinheiro; Ana Cristina Simões e Silva; Regina Maria Pereira
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

3.  Outcomes at one-year post anastomosis from a national cohort of infants with oesophageal atresia.

Authors:  Benjamin Allin; Marian Knight; Paul Johnson; David Burge
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

Review 4.  Are prophylactic anti-reflux medications effective after esophageal atresia repair? Systematic review and meta-analysis.

Authors:  Hiromu Miyake; Yong Chen; Alison Hock; Shogo Seo; Yuhki Koike; Agostino Pierro
Journal:  Pediatr Surg Int       Date:  2018-03-13       Impact factor: 1.827

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.